H. Kienzer

2.2k total citations · 1 hit paper
12 papers, 1.5k citations indexed

About

H. Kienzer is a scholar working on Surgery, Oncology and Otorhinolaryngology. According to data from OpenAlex, H. Kienzer has authored 12 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Oncology and 4 papers in Otorhinolaryngology. Recurrent topics in H. Kienzer's work include Head and Neck Cancer Studies (4 papers), Testicular diseases and treatments (2 papers) and Lung Cancer Treatments and Mutations (2 papers). H. Kienzer is often cited by papers focused on Head and Neck Cancer Studies (4 papers), Testicular diseases and treatments (2 papers) and Lung Cancer Treatments and Mutations (2 papers). H. Kienzer collaborates with scholars based in Austria, Spain and Belgium. H. Kienzer's co-authors include Ricard Mesı́a, Didier Cupissol, Éva Remenár, Thierry Gorlia, Jan B. Vermorken, Carla van Herpen, Jacques Bernier, Jean-Louis Lefèbvre, A Rey and John S. Stewart and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

H. Kienzer

12 papers receiving 1.5k citations

Hit Papers

Cisplatin, Fluorouracil, and Docetaxel in Unresectable He... 2007 2026 2013 2019 2007 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
    2007 1.2k citations Jan B. Vermorken, Éva Remenár et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Kienzer Austria 10 1.0k 831 606 546 202 12 1.5k
Glenn E. Peters United States 26 927 0.9× 1.2k 1.4× 694 1.1× 626 1.1× 388 1.9× 54 2.1k
M. Degardin France 17 1.4k 1.4× 1.0k 1.2× 1.2k 1.9× 838 1.5× 311 1.5× 37 2.3k
Daniëlle Van den Weyngaert Belgium 16 1.2k 1.2× 854 1.0× 673 1.1× 735 1.3× 198 1.0× 26 1.8k
Khai Mun Lee Singapore 16 726 0.7× 604 0.7× 607 1.0× 389 0.7× 105 0.5× 26 1.4k
G. Poissonnet France 23 567 0.6× 500 0.6× 650 1.1× 448 0.8× 174 0.9× 76 1.4k
J. Clark United States 15 435 0.4× 345 0.4× 484 0.8× 363 0.7× 151 0.7× 25 987
Jian‐Sheng Jan Taiwan 14 1.3k 1.3× 917 1.1× 1.1k 1.7× 419 0.8× 208 1.0× 21 1.9k
Jimmy Yu Wai Chan Hong Kong 23 723 0.7× 807 1.0× 532 0.9× 391 0.7× 351 1.7× 70 1.6k
J. Daoud Tunisia 13 318 0.3× 295 0.4× 359 0.6× 158 0.3× 98 0.5× 94 754
Susan Loong Singapore 8 525 0.5× 377 0.5× 477 0.8× 193 0.4× 101 0.5× 12 960

Countries citing papers authored by H. Kienzer

Since Specialization
Citations

This map shows the geographic impact of H. Kienzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Kienzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Kienzer more than expected).

Fields of papers citing papers by H. Kienzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Kienzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Kienzer. The network helps show where H. Kienzer may publish in the future.

Co-authorship network of co-authors of H. Kienzer

This figure shows the co-authorship network connecting the top 25 collaborators of H. Kienzer. A scholar is included among the top collaborators of H. Kienzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Kienzer. H. Kienzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Mesı́a, Ricard, Fernando Rivera, Andrzej Kawecki, et al.. (2010). Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 21(10). 1967–1973. 78 indexed citations
3.
Licitra, Lisa, F. Rolland, Carsten Bokemeyer, et al.. (2009). Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. Journal of Clinical Oncology. 27(15_suppl). 6005–6005. 16 indexed citations
4.
Vermorken, Jan B., Éva Remenár, Carla van Herpen, et al.. (2007). Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. New England Journal of Medicine. 357(17). 1695–1704. 1201 indexed citations breakdown →
5.
Vermorken, Jan B., Ricardo Hitt, Lionnel Geoffrois, et al.. (2007). 5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME). European Journal of Cancer Supplements. 5(4). 324–324. 18 indexed citations
6.
Hulla, Wolfgang, et al.. (2002). Perikarditis als Erstmanifestation einer Retroperitonealfibrose - ein Fallbericht. Wiener Medizinische Wochenschrift. 152(9-10). 230–232. 2 indexed citations
7.
Kienzer, H., et al.. (2000). Extravasation of Oxaliplatin (Eloxatin<sup>®</sup>) – Clinical Course. Oncology Research and Treatment. 23(5). 468–471. 19 indexed citations
8.
Fridrik, Michael, Gerald Jäger, H. Kienzer, et al.. (1998). Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma. European Journal of Cancer. 34(10). 1560–1564. 20 indexed citations
9.
Pont, Jörg, et al.. (1994). Extragonadal malignant germ cell tumor of the lung. Journal of Thoracic and Cardiovascular Surgery. 107(1). 311–312. 4 indexed citations
10.
Pont, Jörg, Elisabeth Puchhammer‐Stöckl, Andreas Chott, et al.. (1992). Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. British Journal of Haematology. 80(2). 160–165. 52 indexed citations
11.
Kienzer, H., et al.. (1991). Carboplatin, Methotrexate and Vinblastin (Carbo-MV) for Advanced Urothelial Cancer A Phase II Trial. American Journal of Clinical Oncology. 14(4). 328–330. 18 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Glenn E. Peters Breakdown of academic impact, for papers by M. Degardin Breakdown of academic impact, for papers by Daniëlle Van den Weyngaert Breakdown of academic impact, for papers by Khai Mun Lee Breakdown of academic impact, for papers by G. Poissonnet Breakdown of academic impact, for papers by J. Clark Breakdown of academic impact, for papers by Jian‐Sheng Jan Breakdown of academic impact, for papers by Jimmy Yu Wai Chan Breakdown of academic impact, for papers by J. Daoud Breakdown of academic impact, for papers by Susan Loong
Rankless by CCL
2026